GlobeNewswire Clinical StudiesOriginal article
ViroMissile Completes First Dose Cohort of Phase I Trial of Intravenously-Dosed IDOV-2; Safety Review Committee Clears Advancement to Next Cohort
Phase 1positiveIDOV-2Positive
AI Analysis
Summary
ViroMissile completed the first dose cohort of its Phase 1 trial of IDOV-2 in patients with advanced solid tumors, with the independent Safety Review Committee clearing advancement to the next higher dose cohort. The trial is being conducted in the United States and Australia.
Clinical Trial Data
Phase
Phase 1
NCT ID
Outcome Details
Safety Review Committee cleared advancement to next dose cohort
Importance:5/10
Sentiment:
0.70
oncologyimmunotherapyoncolytic virusfirst-in-humansafety review
Read the original article
Published by GlobeNewswire Clinical Studies on October 1, 2026 12:30 PM